Abstract. The application of 7-ethyl-10-hydroxycamptothecin (SN-38) in cancer treatment is limited by its low solubility. This study is to develop a liposome-entrapped formulation of SN-38 (LE-SN38) to solve the obstacle and to evaluate its pharmacokinetic profile in dogs and tissue distribution in mice. LE-SN38 which is more likely to be suitable for large-scale production was prepared by the carrier-deposition method. An UPLC-MS/MS method was used to determinate the concentration of SN-38 in this study. LE-SN38 was cleared rapidly from dog plasma within 1 h, and the AUC 0−∞ values of three dosages of LE-SN38 indicated an apparent dose-dependent manner. As for the distribution study, the peak of SN-38 levels in most tissues were detected within 10 min after LE-SN38 administration. In addition, concentration of SN-38 in most tissues except kidney and heart in LE-SN38 group was higher than that in irinotecan hydrochloride (CPT-11) group generally, whereas the administrated CPT-11 had 20 times dosage compared to LE-SN38. LE-SN38 was rapidly eliminated from dog plasma and manifested linear dynamics in dose range of 0.411-1.644 mg/kg. The distribution behavior of SN-38 is altered in a liposome-based delivery system. At the same time, LE-SN38 has lower toxicity compared to CPT-11 in some degree.
INTRODUCTION
7-Ethyl-10-hydroxycamptothecin (SN-38) is the biological active metabolite of irinotecan hydrochloride (CPT-11). CPT-11 has shown clinical activity against colorectal cancer and other malignances, but it just acts as a prodrug and has to be transported to its active metabolite, SN-38, by various enzyme systems (1) (2) (3) . And the metabolic conversion rate is only 2-8% in spite of the fact that CPT-11 could be converted to SN-38 in both liver and tumor tissues (4, 5) . In addition, it not only poses significant life threatening toxicity risks but also complicates the clinical management of patients, as the transformation from CPT-11 to SN-38 is full of variable between patients (6). Moreover, SN-38 is approximately 100-1000-fold more cytotoxic than the parent drug (CPT-11) (7) (8) (9) . Due to its high anticancer activity without any conversion, the direct use of SN-38 would have a very broad application prospects. And it is more possible to be recognized by doctors and patients. However, SN-38 undergoes pH-dependent conversion of pharmacologically active lactone ring to inactive carboxylate form at pH >6 (10) . And the active lactone ring has poor solubility in aqueous solutions and is practically insoluble in most pharmaceutically acceptable excipient, as it was reported that the solubility of SN-38 in water, pH 3.5 and 7.4 buffers were assessed as 11-38, 7.2, and 36 μg/ml, respectively (11) . Hence, the further use of SN-38 in clinic is limited by its low solubility and stability, as well as its severe toxicity (12) .
These drawbacks above can potentially get over by loading the drug into delivery system, particularly liposome. By using a liposome system, drug solubility could be enhanced and the toxicity of loaded anticancer agents would be reduced as well. What is more, it could also improve stability of loaded drugs by protecting the compound from in vivo conditions like acid or alkaline conditions (13) . These characters are exactly what the optimization of SN-38 delivery needs. Therefore, here, it would be a wise choice to develop a liposome-based formulation of SN-38.
It is well-known that a good understanding of drugs' in vivo behavior and the proper knowledge on the distribution is vital to investigate the action mechanism and the major target sites of the product (14) .
The objective of this study is to develop a liposome-based formulation of SN-38 and to evaluate its pharmacokinetic profile and biological distribution using UPLC-MS/MS. It is expected that this experiment could provide helpful information for preclinical and clinical studies. 
MATERIALS AND METHODS

Materials and Animals
Preparation of Liposome-Encapsulated SN-38
The carrier-deposition method was used for liposome-entrapped formulation of SN-38 (LE-SN38) preparation (15) . Briefly, Solutol HS® 15 was solubilized in anhydrous ethanol and then transferred into a round-bottom flask which contains SN-38, cholesterol, and soybean phospholipid. After dissolution, the resulting mixture and glucose powder were rotated under ultrasonic condition for uniform mixing. Then the solution was evaporated to a thin film and rehydrated with phosphate-buffered saline (PBS) containing 10% mannitol by magnetic stirring. The hydration process was performed at 55°C. Ten minutes later, a homogeneous dispersion was formed and immediately sonicated at 400 W power for 5 min using probe sonicator (S-4000-010, Misonix, USA), and the whole processes was carried out in ice bath. The resulting was filtered using a 0.22 μm filter before being transferred into 10 ml vials. Lyophilization was operated by a FD-1 freeze drier, which comprised the following steps: pre-freezing at −40°C for 12 h and then drying for 8 h under the pressure of 30 Pa.
Characterization of LE-SN38
Drug entrapment efficiency was carried out on a mini-column centrifugation method (16, 17) . Sephadex G-50 was filled to a column (1.0 × 10 cm) which was applied to separate free drug from SN-38 liposome. Briefly, 0.5 ml of the SN-38 liposome suspension was loaded into the gel column. Subsequently, it was centrifuged for 2 min and then eluted by 0.5 ml PBS and centrifuged again. The procedure was repeated twice. Then all the eluent, the solution of liposomes enveloping SN-38, was collected. After that, 0.5 ml of the eluent and uneluted LE-SN38 were separately diluted by methanol. The amount of SN-38 encapsulated into liposomes was determined by UV spectrophotometer.
W enveloped was the concentration of SN-38 enveloped in liposomes; W total was the concentration of SN-38 in liposome solution.
The zeta potential and particle size of LE-SN38 were performed on a laser light scattering Zetasizer (Nano-ZS90, Malvern, UK) at 25°C.
Pharmacokinetic Studies
The pharmacokinetic study was carried out on beagle dogs. Before the experiment day, nine of these dogs were fasted overnight but allowed free access to water. Then the dogs were randomly divided into three groups and received injections of 0.411, 0.822, and 1.644 mg/kg single dose of LE-SN38, respectively. The intravenous drip was conducted for about 30 min, then 2 ml of blood samples were collected into heparinized centrifuge tube at 5 min, 10 min 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h after drug administration. The plasma samples were centrifuged and then stored at −40°C until determination.
Tissue Distribution Studies
The tissue distribution experiment was studied on mice. There were eight groups with six mice in each group. For the first four groups (LE-SN38 groups), 4 mg/kg of LE-SN38 was given intravenously via the tail vein, and as for the other four groups (CPT-11 groups), CPT-11 was injected at a dose of 80 mg/kg. At 10, 30, 120, and 360 min after administration, the mice were immediately sacrificed, and organs including heart, liver, spleen, lung, kidney, and intestine were collected; then they were rinsed with saline and then stored at −40°C until analysis.
Sample Analysis
Sample Preparation
Samples were thawed to room temperature before dealing with them. Then the tissues were homogenized with physiological saline at the ratio of 1:10 (g/ml) for the liver, spleen, lung, and intestine and 1:2 (g/ml) for the heart and kidney to get tissue homogenate samples. An aliquot of 100 μl IS solutions (50 ng/mL) was added to 100 μl of matrix sample in 1.5 ml microcentrifuge tubes. The sample mixture was vortexed for 30 s at room temperature. Next, 400 μl of acetonitrile (containing 0.5% acetic acid) was added and vigorously vortexed for 1 min (18) . After centrifugation, the supernatant was extracted and transferred to another clean centrifuge tube and evaporated under N 2 flow at 50°C. Then 100 μl 0.1% formic acid-acetonitrile (70:30, v:v) was added and vortexed for 30 s. After being centrifuged for 10 min, 10 μl of the supernatant was injected for analysis.
UPLC-MS/MS Conditions
SN-38 and CPT (IS) were separated using an ACQUITY UPLC®BEH C18 column (2.1 × 50 mm, 1.7 μm, Waters, USA) at 30°C. It is a gradient elution with acetonitrile (A) and water (B, containing 0.1% formic acid) as the mobile phase, and the flow rate was 0.2 ml/ min. The initial mobile phase composition was A-B (20:80, v/v) with a 0.1 min held and followed by a linear increase to A-B (99:1, v/v) over a 0.1 min period, then held for 0.8 min, and finally returned to A-B (20:80, v/v) during 0.5 min. The total time was 4 min with an injection 10 μl for analysis (19) (20) (21) .
The Waters Xevo TQD triple quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) equipped with an electrospray ion source was used for mass detection. The capillary voltage, cone voltage, and desolvation temperature were 3.05 kV, 47 V, and 300°C, respectively. Nitrogen was used as the desolvation gas (650 l/h) and cone gas (50 l/h). And the multiple reaction monitoring (MRM) was used at the transitions of m/z 393.3 → 349.2 for SN-38 and m/z 349.2 → 305.3 for IS, respectively.
The method was validated for the quantification of SN-38 in dog plasma and mice tissue samples. The calibration curves were linear within 0.5-500 ng/ml in dog plasma and within 1-500 ng/ml in mice tissues (r = 0.9974-0.9995). The lower limit of quantification (LLOQ) was 0.5 ng/ml in plasma and the precision was 9.53% with accuracy of 97.32%. In tissue samples, the LLOQ was 1 ng/ml, and its precision was ranging from 4.65 to 8.46% with accuracy from 94.9 to 105.5%. The intra-and inter-day precision at three concentrations (1, 50, and 500 ng/ml) was less than 10%. The recoveries were accessed by comparing peak area ratios of extracted QC samples with the blank plasma and blank tissue samples spiked with SN-38 after protein precipitation at the three concentrations (1, 50, and 500 ng/ml), having a result of 92.25-98.45 and 90.33-93.64%, respectively. The absolute matrix effect values were in the range of 94.43-105.13% for plasma and 90.67-103.23% for tissue homogenate. These results indicated that there was no significant matrix effect for SN-38 in the matrix sample for this UPLC-MS/MS determination.
Statistical Analysis of Data
All measurements were taken at least in triplicate. Results were represented as mean ± SD. The non-compartmental pharmacokinetic data were carried with Drug and Statistics 2.0 (DAS 2.0) software (Mathematical Pharmacology Professional Committee of China, Shanghai, China). Statistical analysis of the study was calculated with SPSS 11.5 software. It was considered to be statistically significant with values of P < 0.05.
RESULTS
Preparation of Liposome-Encapsulated SN-38
The carrier-deposition method was used to prepare LE-SN38. The concentration of SN-38 for the optimized formulation was 1 mg/ml, and the weight percent ratios of drug-tolipids and SPC to cholesterol was 1:30 and 1:6, respectively. Lyophilization was adopted to enhance the stability of LE-SN38 in the formulation. However, vesicle fusion and leakage of contents can appear for the liposome solution in the absence of any protective agents (22) (23) (24) (25) . In this study, freshly prepared LE-SN38 suspensions were lyophilized with different excipients to assess for cryoprotective activity. And the results were shown in Table I . The structure of the freezedrying cakes was obviously different while mixing with different protective agents. Both mannitol and dextran groups could contain integrity freeze-drying cakes, but the dextran group expressed with a larger size and some crystal. Hence, mannitol was an ideal choice.
In another study, liposomes were freeze-dried at different concentrations of mannitol, including 3, 5, 8, and 10% (w/v). It showed that 10% mannitol (lipid to mannitol ratios of 1:3.3 (w/w)) could inhibit liposomal fusion or degradation during lyophilization, and the results were assessed by the appearance, reconstitution, and the particle size of the reconstitution solution. And the entrapment efficiency has no significant change. Hence, 10% mannitol tends to be an ideal choice to effectively protect LE-SN38 during freeze-drying procedures.
The EE, particle size, and zeta potential of LE-SN38 were obtained and shown in Table II. The mean particle size was 130 ± 46 nm (<200 nm), with an EE of 91.7 ± 4.2% for LE-SN38 before lyophilized. Because zeta potential of LE-SN38 was −0.387 mV, the low stability should be improved. Here, lyophilization might help to this situation in some degree.
Pharmacokinetic Studies
The pharmacokinetic study was performed on beagle dogs by i.v. drip administration of 0.411, 0.822, and 1.644 mg/ kg LE-SN38. The non-compartmental pharmacokinetic parameters resulting from DAS 2.0 software were listed in Table III .
The concentration-time profiles of SN-38 are shown in Fig. 1 . According to the figure, we can infer that the plasma concentration of SN-38 was initially decreased rapidly for all three dose groups, and then equilibrium was reached at 6 h. The primary rapid decline indicates that SN-38 might have drive away from the plasma and been distributed into the other tissues, which was confirmed by our tissue distribution study in mice.
Furthermore, we found that the fold increased in dosage (0.411 versus 0.822 versus 1.644 mg/kg) led to an approximate fold increase in AUC 0−∞ (92.5 versus 165.3 versus 317.1 ng/ml × h). No significant difference appeared (P > 0.05) in systemic clearance and t 1/2 at each dose, that is to say LE-SN38 may have linear pharmacokinetics in dose range of 0.411-1.644 mg/ kg.
In addition, during the whole study, none of the nine dogs exhibited gastrointestinal reaction, such as vomiting and diarrhea. And there was no significant difference in body weight in dogs (data not shown). This might indicate that LE-SN38 has lower toxicity compared to CPT-11. Thus, LE-SN38 may provide a potential therapeutic option for cancer treatment. Table III AUC area under the curve, t 1/2 half-life, V apparent volume of distribution, CL clearance 
Tissue Distribution Studies
Peak SN-38 levels were measured in most tissues within 10 min of treatments (Fig. 2) ; the results suggested that they both underwent a rapid distribution to tissues. For LE-SN38 group, the AUC 0-6 h in these tissues was detected in the following order: liver > spleen > lung > intestine > kidney > heart. It can be concluded that SN-38 might mainly concentrate in the liver, spleen, and lung, as they accounted for 91%. the concentrations of SN-38, with the exception of the kidney and heart, were generally higher than those following treatment with 20-fold doses of CPT-11 (Fig. 3) . The AUC 0-6 h of LE-SN38 in the spleen, liver, and lung were significant higher than that of CPT-11. The AUC 0-6 h for LE-SN38 was improved by 385% in the liver, 670% in the spleen, and 465% in the lung compared to CPT-11 (Table IV) . These results demonstrated that LE-SN38 altered the distribution behavior of SN-38 in tissues.
DISCUSSION
In this study, LE-SN38 was prepared by carrierdeposition method, and it is a modified film dispersion method. Using this method, drug and lipids were precipitated on glucose to form solid dispersion during the evaporation. Then it can be scraped from the sides of the bottle and milled to a fine powder to obtain a more complete drying. On the other hand, glucose that is soluble in water could accelerate the hydration rate and shorten the hydration time. Moreover, the operator could timely adjust the accident occurring during the preparation (26) . Therefore, the stability and quality of LE-SN38 could be enhanced by this method, and the preparation process could be more simple.
On the other hand, the product in this study would be stored in solid form as freeze-dried powder, and it leaves no contact with the hydration medium which could avoid the hydrolysis of phospholipids. Therefore, it has no physical stability and drug leakage problems which are found in the storage of liposome solution (27) (28) (29) (30) . In summary, this method solves the problem that restricted industrial production. So it is more likely to be put into large-scale production.
Recently, several methods have been reported to be applied for the quantification of SN-38 and CPT-11. But the method for determination of SN-38 in dog plasma only utilized HPLC with fluorescence detector, and it required over 6 min and 200 μl or more plasma as sample (31) (32) (33) . Hence, we would like to investigate a determination method by which shorter analysis time and lower LLOQ could be achieved. To the best of our knowledge, the bio-analytical method described here is the first UPLC-MS/MS method for dog plasma quantification of SN-38. A good separation was achieved without using any ion-pairing agents. And it has lower LLOQ (0.5 ng/ml) in dog plasma than the previous reports determined with fluorescence detector (1 ng/ml). Moreover, it not only shortens the analysis time but also uses a smaller sample volume (0.1 ml). These results suggest that the UPLC-MS/MS method develop here is suitable.
In the pharmacokinetic study, LE-SN38 was quickly decreasing from dog plasma. It was reported that peak SN-38 levels were quickly measured in the liver after LE-SN38 treatment (34) , and our distribution study in mice also showed that peak tissue levels were measured within 10 min in most tissues after LE-SN38 treatment. Furthermore, the plasma concentration in three dose groups followed the same eliminating trend. And within the dose range of 0.411-1.644 mg/kg, the AUC is proportional to dose. This suggested that the safety of LE-SN38 administration is enhanced and it would also provide helpful information on clinical medicine.
On the other hand, a comparative distribution experiment was studied between LE-SN38 and CPT-11 by measuring the concentration of SN-38 in mice tissues. Compared to CPT-11, SN-38 has relatively high drug distribution in the liver, lung, and spleen, and it still maintains a high concentration in these tissues 6 h later. This means that it might have good therapeutic effect for the treatment of these cancers (35) , and the retention time of SN-38 was prolonged in these organs by a liposome-based formulation. The increased uptake in the liver, lung, and spleen was probably mediated by the RES system for the characterization of liposome. Furthermore, concentration of SN-38 in the heart and kidney tended to be much lower than that of CPT-11 group, providing important evidence for reduced toxicity of LE-SN38. And this is also consistent with our pharmacokinetic study. All the results suggest that the distribution behavior of SN-38 is altered in a liposome-based delivery system.
CONCLUSION
In this study, in order to surmount the solubility and stability obstacle of SN-38, we have prepared a liposomebased SN-38 formulation. SN-38 lyophilized powder was prepared by carrier-deposition method, and it is stable during the storage and more possible to be put into large-scale production. Then we evaluate the pharmacokinetic profile of LE-SN38 in beagle dogs as well as its biological distribution in mice using an UPLC-MS/MS method. LE-SN38 was rapidly eliminated from dog plasma and followed linear pharmacokinetic pattern, and the distribution behavior of SN-38 was also altered in the liposome-based formulation. It is expected that this study could help to further clarify the in vivo behavior of LE-SN38 and provide available information for clinical application.
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